(Cost)-Effectiveness of ABFT for Suicidal Youth.
Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · Jul 19, 2023
Trial Information
Current as of November 14, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a type of therapy called Attachment-Based Family Therapy (ABFT) to see if it is more effective than current treatments for young adults who have serious thoughts about suicide. The trial is taking place in Belgium and the Netherlands, aiming to include 138 participants aged between 18 and 25 years old. To participate, individuals must have a high level of suicidal thoughts and need to have at least one parent or caregiver involved in their treatment. The goal is to find out if ABFT can reduce suicidal thoughts and attempts better than the existing treatment options and if it offers good value for money.
Participants in the trial can expect to receive either ABFT or the standard treatment available. The study will take place in various settings, including hospitals and mental health centers. By participating, individuals will contribute to important research that could improve care for young adults at high risk of suicide, helping to shape future treatment guidelines and support for their families.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged between 18 and 25.
- • A score above 31 on the SIQ-JR (the cut-off for suicidality).
- • Have at least one primary parent or caregiver that participates in the assessment and treatment. This could be a biological parent, stepparent, grandparent, other relative, or a foster parent.
- Exclusion Criteria:
- • Other DSM-5 disorders: substance dependency: severe alcohol or cannabis use disorder, all other substances: modest or severe substance use disorder.
- • Severe conduct disorder.
- • Evidence of psychotic features or prior psychosis (assessed with the SCID-5-S).
- • Severe cognitive impairment (e.g., mental retardation, severe developmental disorders) as evidenced by educational records, parental report and/or clinical impression.
- • Other circumstances that might affect participation (e.g., severe medical disorder, relocation).
About Academisch Medisch Centrum Universiteit Van Amsterdam (Amc Uva)
The Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is a leading academic medical center in the Netherlands, dedicated to advancing healthcare through innovative research, education, and patient care. Affiliated with the University of Amsterdam, AMC-UvA integrates clinical practice with cutting-edge biomedical research, fostering a multidisciplinary approach to medical challenges. The institution actively engages in clinical trials to enhance treatment options and improve patient outcomes, while promoting collaboration among healthcare professionals, researchers, and academic institutions globally. With a commitment to excellence and a focus on translational medicine, AMC-UvA plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amsterdam, Noord Holland, Netherlands
Oss, Noord Holland, Netherlands
Tongeren, Limburg, Belgium
Gent, Oost Vlaanderen, Belgium
Kortenberg, Vlaams Brabant, Belgium
Leuven, Vlaams Brabant, Belgium
Leuven, Vlaams Brabant, Belgium
Merchtem, Vlaams Brabant, Belgium
Eindhoven, Noord Brabant, Netherlands
Oss, Noord Brabant, Netherlands
Amsterdam, Noord Holland, Netherlands
Amsterdam, Noord Holland, Netherlands
Santpoort Noord, Noord Holland, Netherlands
Amersfoort, Utrecht, Netherlands
Patients applied
Trial Officials
Nadia van der Spek, PhD
Study Director
Academic Medical Center (AMC)
Claudi Bockting, professor
Principal Investigator
Academic Medical Center (AMC)
Guy Bosmans, Professor
Study Director
KU Leuven
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported